670 results on '"Peereboom, David"'
Search Results
2. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
3. Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
4. 18F-fluciclovine PET/CT to distinguish radiation necrosis from tumor progression for brain metastases treated with radiosurgery: results of a prospective pilot study
5. Concurrent Lapatinib With Brain Radiation Therapy in Patients With HER2+ Breast Cancer With Brain Metastases: NRG Oncology–KROG/RTOG 1119 Phase 2 Randomized Trial
6. Primary Central Nervous System Lymphoma: Neuro-Oncologic Approach
7. Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium’s first workshop on CNS drug delivery
8. Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
9. A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).
10. Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas
11. Sex-Specific Differences in Low-Grade Glioma Presentation and Outcome
12. Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma
13. 151 Exceptional Responders to Base Excision Repair (BER) Inhibition for Recurrent Glioblastoma Display Enrichment for DNA Damage Response Pathways: RNA Sequencing Analysis From a Multicenter Trial
14. Safety and Feasibility of JAK Inhibitor Ruxolitinib in Newly-Diagnosed High-Grade Gliomas (CRUX): Final Trial Report
15. 501 Systemic Immunological Suppression in Glioblastoma Is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-Seq) From a Randomized Controlled Trial
16. MGMT Methylation and Differential Survival Impact by Sex in Glioblastoma
17. Miscellaneous Metastases
18. Correction to: Primary Central Nervous System Lymphoma: Neuro-Oncologic Approach
19. Primary Central Nervous System and Retinal Lymphoma
20. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer
21. Breast Cancer Brain Metastases: Challenges and Opportunities.
22. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma
23. Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma
24. Neurological Complications of Sarcomas
25. Evaluation and Workup of Leptomeningeal Disease
26. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era
27. Contributors List
28. Approach to the patient with CNS lymphoma
29. CTIM-06. A PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GLIOBLASTOMA: EXPLORING THE PROGNOSTIC VALUE OF TREATMENT-INDUCED CD8+CD57+ T-CELLS AS A MARKER FOR SURVIVAL
30. CTIM-19. ONCOLYTIC DNX-2401 VIROTHERAPY PLUS PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA: A PHASE 1/2 TRIAL
31. CTNI-08. TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL
32. IMMU-34. SYSTEMIC IMMUNE SUPPRESSION IN GLIOBLASTOMA IS TARGETED BY CONCURRENT VEGF AND PD-1 INHIBITION IN A DOSE-DEPENDENT MANNER: TRANSCRIPTOMIC FINDINGS THROUGH CITE-SEQ FROM A RANDOMIZED CONTROLLED TRIAL
33. DNAR-05. EXCEPTIONAL RESPONDERS TO BASE EXCISION REPAIR (BER) INHIBITION FOR RECURRENT GLIOBLASTOMA DISPLAY ENRICHMENT FOR DNA DAMAGE RESPONSE PATHWAYS: RNA SEQUENCING ANALYSIS FROM A MULTICENTER TRIAL
34. CTNI-21. PHASE I STUDY OF BTK INHIBITOR IBRUTINIB WITH TEMOZOLOMIDE AND RADIATION IN NEWLY-DIAGNOSED GLIOBLASTOMA (EQUILIBRIUM): FINAL TRIAL REPORT
35. Secondary somatic glioblastoma arising from a mature ovarian cystic teratoma in a patient with underlying Li-Fraumeni Syndrome
36. A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)
37. Risk Factors for Malignant Transformation of Low-Grade Glioma
38. Phase II study of Dovitinib in recurrent glioblastoma
39. Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
40. Intensity modulated radiation therapy with pulsed reduced dose rate as a reirradiation strategy for recurrent central nervous system tumors: An institutional series and literature review
41. Miscellaneous Metastases
42. Current Medical Treatment of Glioblastoma
43. First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
44. Supplementary Data 3 from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
45. Supplementary Data 2 from A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
46. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
47. Vitreoretinal Lymphoma: Staging and Treatment
48. Primary Central Nervous System and Retinal Lymphoma
49. The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases
50. Novel Therapeutic Approaches in Neoplastic Meningitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.